Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:37 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $27.1M (4.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 26, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $634.2M | $528.3M | $399.4M | $329.2M | $305.5M |
| Cost of revenue | $72.9M | $52.9M | $37.3M | $38.6M | $34.5M |
| Gross profit | $561.3M | $475.4M | $362.0M | $290.6M | $271.0M |
| Operating expenses | $528.5M | $450.5M | $439.2M | $502.8M | $477.5M |
| Research and development | $135.8M | $109.4M | $152.4M | $276.7M | $272.0M |
| Selling, general and administrative | $383.5M | $323.4M | $275.3M | $213.0M | $192.7M |
| Operating income | $32.8M | $24.9M | -$77.2M | -$212.1M | -$206.4M |
| Interest expense | – | – | $50.1M | $37.1M | $32.5M |
| Income tax | $27.3M | $27.4M | $1.48M | -$5.47M | $8.91M |
| Net income | -$27.1M | -$56.1M | -$151.6M | -$236.6M | -$250.5M |
| EPS, basic | $-0.09 | $-0.18 | $-0.51 | $-0.82 | $-0.92 |
| EPS, diluted | $-0.09 | $-0.18 | $-0.51 | $-0.82 | $-0.92 |
| Weighted shares, basic | 308.4M | 304.4M | 295.2M | 289.1M | 271.4M |
| Weighted shares, diluted | 308.4M | 304.4M | 295.2M | 289.1M | 271.4M |
| Margins and growth | |||||
| Gross margin | 88.5% | 90.0% | 90.7% | 88.3% | 88.7% |
| Operating margin | 5.2% | 4.7% | -19.3% | -64.4% | -67.6% |
| Net margin | -4.3% | -10.6% | -38.0% | -71.9% | -82.0% |
| Revenue growth, year over year | +20.0% | +32.3% | +21.3% | +7.8% | +17.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 26, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $214.0M | $213.8M | $247.0M | $148.8M | $245.2M |
| Short-term investments | $79.5M | $36.2M | $39.2M | $144.8M | $237.3M |
| Accounts receivable | $115.3M | $101.1M | $87.6M | $66.2M | $52.7M |
| Inventory | $228.8M | $118.8M | $59.7M | $23.8M | $26.8M |
| Total current assets | $676.2M | $504.7M | $483.1M | $423.8M | $596.8M |
| Property, plant and equipment | $27.1M | $29.4M | $31.7M | $30.8M | $42.5M |
| Goodwill | $197.8M | $197.8M | $197.8M | $197.8M | $197.8M |
| Intangible assets | $13.9M | $17.2M | $20.5M | $23.0M | $23.0M |
| Total assets | $949.9M | $785.0M | $777.9M | $724.2M | $905.1M |
| Accounts payable | $28.6M | $12.9M | $15.1M | $15.4M | $21.5M |
| Total current liabilities | $237.8M | $148.7M | $167.7M | $139.0M | $146.0M |
| Long-term debt | $392.7M | $390.1M | $387.9M | $392.0M | $389.4M |
| Total liabilities | $675.6M | $591.0M | $617.7M | $601.1M | $597.8M |
| Shareholders' equity | $274.2M | $194.0M | $160.2M | $123.0M | $307.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 26, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $33.1M | -$33.9M | -$69.1M | -$166.6M | -$202.5M |
| Capital expenditures | $3.30M | $3.55M | $7.44M | $3.77M | $3.88M |
| Free cash flow | $29.8M | -$37.4M | -$76.5M | -$170.3M | -$206.4M |
| Depreciation and amortization | $7.46M | $8.55M | $7.87M | $5.34M | $6.21M |
| Stock-based compensation | $87.4M | $84.9M | $86.1M | $76.5M | $57.8M |
| Investing cash flow | -$46.4M | -$560.0K | $98.1M | $92.3M | $78.8M |
| Financing cash flow | $610.0K | $5.12M | $61.7M | -$7.46M | $212.1M |
| Net change in cash | $600.0K | -$33.4M | $97.0M | -$96.3M | $83.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 13.8% | 16.1% | 21.6% | 23.2% | 18.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Feb 12, 2026 | 314.0M | +4.6% | SEC |
| Oct 24, 2025 | 308.5M | +3.3% | SEC |
| Jul 25, 2025 | 308.2M | +3.9% | SEC |
| Apr 24, 2025 | 307.9M | +4.0% | SEC |
| Feb 10, 2025 | 300.1M | +1.6% | SEC |
| Oct 25, 2024 | 298.8M | +1.9% | SEC |
| Jul 26, 2024 | 296.6M | +3.3% | SEC |
| Apr 25, 2024 | 296.2M | +4.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.